Know-How Based on More Than 170,000 Cell-Processing Cases
First written in FY2017-Q2. 4 of 7 entries say "Advanced", first in FY2019. Latest entry: 2026-05-27.
The whole theme swung hardest in 2025: 1 of 10 companies on the "Worse" side.
7 other companies' latest entry also says "Advanced".
- 2026-05-27AdvancedPresentation materials on financial results
「Approximately 200,000 procedures」
The cumulative number of specified cellular product processing procedures was approximately 200,000 as of 31 March 2026. - FY2023AdvancedAnnual report
「The number of cell-processing cases handled to date has reached approximately 194,000.」
The cell-processing track record was updated from approximately 192,000 cases in the previous disclosure to approximately 194,000 cases. - FY2022AdvancedAnnual report
「The number of cell-processing cases handled to date has reached approximately 192,000.」
The stated cell-processing track record was updated from more than 180,000 cases to approximately 192,000 cases. - FY2019AdvancedAnnual report
「Based on the expertise and experience we have developed through more than 180,000 cell-processing cases to date,」
The stated cell-processing track record was updated from more than 170,000 cases to more than 180,000 cases. - FY2017RestatedAnnual report
「Based on the expertise and knowledge the group has developed through providing its Comprehensive Support Service for Immunotherapy,」
The company continues to describe the expertise and knowledge accumulated through its Comprehensive Support Service for Immunotherapy as the foundation for its cell-processing and CDMO businesses. - FY2017-Q3RestatedAnnual report
「Under this new legal framework, the group is establishing in Shinagawa, near Haneda Airport, a cell culture and processing facility that consolidates the expertise and experience it has developed through more than 170,000 cell-processing cases,」
The company reiterates that its more than 170,000 cell-processing cases and the Shinagawa cell culture and processing facility form the foundation of its contract business. - FY2017-Q2First statedAnnual report
「Under these new legal and regulatory frameworks, the Group established a cell culture and processing facility in Shinagawa, near Haneda Airport, consolidating the extensive know-how and experience accumulated through more than 170,000 cell-processing cases. We are working to further expand our cell-processing and CDMO businesses by undertaking the manufacture of specified processed cells and regenerative medical products for pharmaceutical companies, universities and medical and research institutions engaged in regenerative and cellular medicine.」
More than 170,000 cell-processing cases and the resulting know-how and experience are described as the foundation for the Shinagawa cell culture and processing facility and contract business.